π Share this article World Health Organization Raises Concern Over Critical Shortage of Weight-Loss Injections Under 10% of individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the medications. Given over a billion people worldwide now classified as obese, it is advocating for increased and just availability to this class of drugs. Per projections, more than two billion will be obese by 2030 unless action is taken. "Our new guidance affirms that obesity is a lifelong illness that can be addressed with thorough and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to universal access to the treatments that can aid individuals in losing significant weight, says the body. Skinny Jab Scarcity Despite the present most favorable case, the production of such drugs might only reach around 100 million people β fewer than 10% of those who need them, according to the health organization. The guideline urges nations and manufacturers to increase availability, through measures such as voluntary licensing. The intellectual property rights on semaglutide β the main component of Novo Nordisk's Wegovy β is due to expire in a number of nations in 2026. The Way Weight-Loss Jabs Operate GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so people consume fewer calories. Individuals commonly see weight reduction after several weeks of starting on the once-weekly jabs. Studies points to users may put most of the weight back on within a year of discontinuing the medication, as their usual food cravings come back. Being carrying excess weight increases your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Obesity impacts individuals in all nations and was associated with millions of deaths worldwide in 2024, per the health agency.
Under 10% of individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, warns the World Health Organization as it publishes its initial recommendations on the medications. Given over a billion people worldwide now classified as obese, it is advocating for increased and just availability to this class of drugs. Per projections, more than two billion will be obese by 2030 unless action is taken. "Our new guidance affirms that obesity is a lifelong illness that can be addressed with thorough and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to universal access to the treatments that can aid individuals in losing significant weight, says the body. Skinny Jab Scarcity Despite the present most favorable case, the production of such drugs might only reach around 100 million people β fewer than 10% of those who need them, according to the health organization. The guideline urges nations and manufacturers to increase availability, through measures such as voluntary licensing. The intellectual property rights on semaglutide β the main component of Novo Nordisk's Wegovy β is due to expire in a number of nations in 2026. The Way Weight-Loss Jabs Operate GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and boost satiety so people consume fewer calories. Individuals commonly see weight reduction after several weeks of starting on the once-weekly jabs. Studies points to users may put most of the weight back on within a year of discontinuing the medication, as their usual food cravings come back. Being carrying excess weight increases your chance for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and some malignancies. Obesity impacts individuals in all nations and was associated with millions of deaths worldwide in 2024, per the health agency.